GlassScriptPhysician profile
Allison B Hetrick
NPI 1144091943
$1,194.51
in general payments reported to CMS, 2019-2025
14 companies · $614 in 2025
The $614 reported for 2025 was more than what 78% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $581 · 2025: $614.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,169 · Education: $25.64.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,168.87 |
| Education | $25.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $391.66 | 2024-2025 | |
| Ardelyx, INC. | $216.63 | 2024-2025 | Ibsrela |
| Madrigal Pharmaceuticals | $185.92 | 2024 | Rezdiffra, Resmetirom |
| Mimedx Group, INC. | $90.07 | 2025 | |
| Urgo Medical North America, LLC | $88.60 | 2024-2025 | Urgok2, Urgoclean Ag, Vashe Wound Solution 250 Ml (8.5 Fl Oz) Flip Top Cap |
| Paratek Pharmaceuticals, INC. | $42.72 | 2025 | Nuzyra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.64 | 2024 | Trulance, Xifaxan |
| Smith+Nephew, INC. | $29.57 | 2025 | Grafix |
| Celltrion USA INC. | $25.64 | 2024 | Zymfentra |
| Ironwood Pharmaceuticals, INC | $24.86 | 2024 | |
| Solventum Corporation | $23.53 | 2025 | 3m Coban, Promogran Prisma, Activ.A.C. |
| Ipsen Biopharmaceuticals, INC | $16.90 | 2025 | Iqirvo |
| Takeda Pharmaceuticals U.S.A., INC. | $15.31 | 2024 | Entyvio |
| Braintree Laboratories, INC. | $13.46 | 2024 | Sutab, Suflave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Hetrick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.